Topic: checkpoint inhibitors
In a monumental win for patients, Roche’s Tecentriq has a big new breast cancer approval—and another piece of the I-O market all to itself.
Two Big Pharmas are racing toward a new indication in kidney cancer, but thanks to new data from Merck, it may not matter who gets there first.
If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.
BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.
Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
Investors panicked in October when Bristol-Myers Squibb said a request for more data from a key lung cancer trial had pushed back an FDA decision.
For the fourth quarter, analysts expect Keytruda to maintain its lead over Opdivo. But it’s Opdivo that could surprise Wall Street, one analyst says.
In November, Merck said Keytruda had topped chemo at lengthening the lives of esophageal cancer patients. Monday, it showed the win was a big one.
Back in November, Pfizer and Merck KGaA reported that Bavencio had failed a late-stage ovarian cancer trial. And now they can make it two.